(ITGR) Integer Holdings - Overview
Stock: Batteries, Leads, Enclosures, Feedthroughs, Stimulators
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 28.9% |
| Relative Tail Risk | -11.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.97 |
| Alpha | -51.69 |
| Character TTM | |
|---|---|
| Beta | 0.721 |
| Beta Downside | 0.626 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.14% |
| CAGR/Max DD | 0.13 |
Description: ITGR Integer Holdings January 11, 2026
Integer Holdings Corp (NYSE: ITGR) is a contract development and manufacturing organization (CDMO) for medical devices, operating in the United States, Puerto Rico, Costa Rica and other global locations. Its portfolio spans interventional cardiology, structural heart, heart-failure, peripheral vascular, neurovascular, oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, gastroenterology, orthopedics, minimally invasive and general surgery, plus a range of portable devices such as patient monitors, ventilators and ultrasound units.
The firm supplies multi-national original equipment manufacturers (OEMs) and their subsidiaries with high-mix, high-precision components-including implantable pacemakers, defibrillators, spinal-cord stimulators, non-rechargeable and rechargeable batteries, feedthroughs, device enclosures, machined parts and lead sub-assemblies-supporting the cardiac rhythm management, neuromodulation, vascular and advanced surgical markets.
In FY 2023 Integer reported revenue of roughly **$1.2 billion**, a **~6 % year-over-year increase** driven primarily by growth in cardiac rhythm management and portable-device contracts; operating margin stood at **≈ 9 %**, and the company disclosed a **backlog of $2.5 billion**, indicating a solid pipeline of multi-year OEM agreements.
Key macro drivers for Integer’s end markets include an aging U.S. population (the 65-plus cohort is projected to reach 22 % of the population by 2035), rising prevalence of chronic cardiovascular disease, and a continued shift toward outpatient and minimally invasive procedures that increase demand for modular, high-volume device components.
For a deeper, data-rich look at Integer’s valuation and risk profile, you might explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 86.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.54 > 1.0 |
| NWC/Revenue: 31.04% < 20% (prev 30.37%; Δ 0.67% < -1%) |
| CFO/TA 0.06 > 3% & CFO 204.0m > Net Income 86.9m |
| Net Debt (1.25b) to EBITDA (356.3m): 3.51 < 3 |
| Current Ratio: 3.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.6m) vs 12m ago -0.51% < -2% |
| Gross Margin: 26.99% > 18% (prev 0.27%; Δ 2672 % > 0.5%) |
| Asset Turnover: 55.78% > 50% (prev 52.77%; Δ 3.01% > 0%) |
| Interest Coverage Ratio: 5.17 > 6 (EBITDA TTM 356.3m / Interest Expense TTM 45.2m) |
Altman Z'' 3.12
| A: 0.17 (Total Current Assets 778.1m - Total Current Liabilities 209.8m) / Total Assets 3.40b |
| B: 0.28 (Retained Earnings 945.4m / Total Assets 3.40b) |
| C: 0.07 (EBIT TTM 233.5m / Avg Total Assets 3.28b) |
| D: 0.61 (Book Value of Equity 1.01b / Total Liabilities 1.65b) |
| Altman-Z'' Score: 3.12 = A |
Beneish M -2.92
| DSRI: 1.09 (Receivables 417.3m/349.2m, Revenue 1.83b/1.67b) |
| GMI: 1.01 (GM 26.99% / 27.15%) |
| AQI: 0.98 (AQ_t 0.58 / AQ_t-1 0.59) |
| SGI: 1.10 (Revenue 1.83b / 1.67b) |
| TATA: -0.03 (NI 86.9m - CFO 204.0m) / TA 3.40b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of ITGR shares?
Over the past week, the price has changed by -0.47%, over one month by +6.98%, over three months by +29.73% and over the past year by -38.65%.
Is ITGR a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ITGR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85.6 | -1% |
| Analysts Target Price | 85.6 | -1% |
| ValueRay Target Price | 82.7 | -4.3% |
ITGR Fundamental Data Overview February 02, 2026
P/E Forward = 9.5877
P/S = 1.6621
P/B = 1.7354
P/EG = 0.3835
Revenue TTM = 1.83b USD
EBIT TTM = 233.5m USD
EBITDA TTM = 356.3m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 9.12m USD (from shortTermDebt, last quarter)
Debt = 1.31b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.25b USD (from netDebt column, last quarter)
Enterprise Value = 4.30b USD (3.04b + Debt 1.31b - CCE 58.9m)
Interest Coverage Ratio = 5.17 (Ebit TTM 233.5m / Interest Expense TTM 45.2m)
EV/FCF = 25.95x (Enterprise Value 4.30b / FCF TTM 165.5m)
FCF Yield = 3.85% (FCF TTM 165.5m / Enterprise Value 4.30b)
FCF Margin = 9.04% (FCF TTM 165.5m / Revenue TTM 1.83b)
Net Margin = 4.75% (Net Income TTM 86.9m / Revenue TTM 1.83b)
Gross Margin = 26.99% ((Revenue TTM 1.83b - Cost of Revenue TTM 1.34b) / Revenue TTM)
Gross Margin QoQ = 26.98% (prev 27.41%)
Tobins Q-Ratio = 1.26 (Enterprise Value 4.30b / Total Assets 3.40b)
Interest Expense / Debt = 0.71% (Interest Expense 9.37m / Debt 1.31b)
Taxrate = 13.73% (6.31m / 46.0m)
NOPAT = 201.5m (EBIT 233.5m * (1 - 13.73%))
Current Ratio = 3.71 (Total Current Assets 778.1m / Total Current Liabilities 209.8m)
Debt / Equity = 0.75 (Debt 1.31b / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 3.51 (Net Debt 1.25b / EBITDA 356.3m)
Debt / FCF = 7.56 (Net Debt 1.25b / FCF TTM 165.5m)
Total Stockholder Equity = 1.67b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.65% (Net Income 86.9m / Total Assets 3.40b)
RoE = 5.21% (Net Income TTM 86.9m / Total Stockholder Equity 1.67b)
RoCE = 8.16% (EBIT 233.5m / Capital Employed (Equity 1.67b + L.T.Debt 1.19b))
RoIC = 7.13% (NOPAT 201.5m / Invested Capital 2.82b)
WACC = 6.18% (E(3.04b)/V(4.35b) * Re(8.57%) + D(1.31b)/V(4.35b) * Rd(0.71%) * (1-Tc(0.14)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 2.36%
[DCF Debug] Terminal Value 87.45% ; FCFF base≈128.9m ; Y1≈159.0m ; Y5≈270.8m
Fair Price DCF = 170.1 (EV 7.21b - Net Debt 1.25b = Equity 5.96b / Shares 35.0m; r=6.18% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 8.23 | EPS CAGR: -41.51% | SUE: -4.0 | # QB: 0
Revenue Correlation: 96.83 | Revenue CAGR: 11.30% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.35 | Chg30d=+0.003 | Revisions Net=-6 | Analysts=6
EPS next Year (2026-12-31): EPS=6.30 | Chg30d=-0.011 | Revisions Net=-8 | Growth EPS=-0.7% | Growth Revenue=-0.1%